Xie, Yixuan
Liu, Xingyu https://orcid.org/0000-0003-0008-7815
Yi, Li https://orcid.org/0009-0002-2872-2569
Wang, Shunyang
Lin, Zongtao https://orcid.org/0000-0002-6017-338X
Zhao, Chenfeng
Chen, Siyu https://orcid.org/0009-0003-9584-6905
Robison, Faith M.
George, Benson M.
Lebrilla, Carlito B. https://orcid.org/0000-0001-7190-5323
Flynn, Ryan A. https://orcid.org/0000-0001-5013-0442
Garcia, Benjamin A. https://orcid.org/0000-0003-3596-4750
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (AI118891, HD106051, CA196539)
Greater Bay Area Institute of Precision Medicine, I003
Burroughs Wellcome Fund Career Award for Medical Scientists, the Sontag Foundation Distinguished Scientist Award, the Rita Allen Foundation
Article History
Received: 31 May 2024
Accepted: 24 June 2025
First Online: 1 August 2025
Competing interests
: R.A.F. is a stockholder of ORNA Therapeutics. R.A.F. is a board of directors member and stockholder of Chronus Health and Blue Planet Systems. The remaining authors declare no competing interests.